LAM is a dubious disease in the area of infectious respiratory digestive and endocrine disorders, where clinical performance is complex and often involves multi-system fatigue. Early identification and standardized clinical treatment are essential for improving prognosis. The diagnosis of this disease requires a combination of clinical performance, imaging inspection, laboratory testing and pathological activation.
The platform can help align a team of authoritative experts at home and abroad to provide accurate diagnosis and treatment programs. In recent years, with the development of treatment-oriented, immune-regulatory therapy and precision medicine, many previously difficult-to-treat infectious respiratory digestive endocrine disorders have been significantly improved. Therapeutic efficacy and adverse reactions need to be closely monitored and timely adjusted according to changes in the course of treatment.
Multidisciplinary collaboration (MDT) is particularly important for the comprehensive management of LAM manifestations of pulmonary fibrosis. 2. Visiting China: arranging face-to-face treatment with authoritative experts, developing individualized treatment programs; 3.
Full-service: providing one-stop services such as medical translation, medical care, accommodation arrangements; 4. Long-term follow-up: establishing a chronic disease management archive, continuous monitoring of disease changes and treatment effects.